between impaired MBF and adverse prognosis is depicted in Figure 1A.

In total, 22 (17%) patients underwent late coronary revascularization on 28 vessels. At baseline evaluation, none of those vessels had obstructive CAD. On regional analysis, absolute stress MBF (1.2 ± 0.4 ml·g⁻¹·min⁻¹ vs 1.5 ± 0.5 ml·g⁻¹·min⁻¹; \( P < 0.001 \)) and MBF reserve (2.0 ± 0.6 vs 2.5 ± 0.9; \( P = 0.026 \)) were lower in vessels that would later undergo revascularization than in the other coronaries with nonobstructive CAD (Figure 1B).

Present results show for the first time that a depressed global MBF reserve obtained with dynamic CZT imaging can individuate patients at risk of MACE, independently of relative perfusion parameters and of global CAD burden. In our cohort, MACE concentrated in patients with depressed MBF reserve that showed a cumulative event rate of 29% vs 5% in those with preserved perfusion (\( P < 0.001 \)).

Although the association between CAD burden and adverse cardiac events has been already reported (4), their possible interaction with CZT-derived MBF data was still unknown. Although present data confirmed that the “CAD score”—as an indicator of overall atherosclerotic burden—is a predictor of MACE (3), CZT-derived MBF reserve remained significantly associated with adverse events at follow-up. Moreover, even in the absence of obstructive CAD at baseline, the presence of an impaired regional MBF could identify those vessels that would more frequently require a late coronary revascularization (Figure 1B), likely because of heightened CAD progression. In conclusion, we found that in stable CAD patients, CZT-derived MBF data predicted adverse cardiac events independently of overall CAD burden.

Riccardo Liga, MD, PhD
Danilo Neglia, MD, PhD
Annette Kusch, RT
Brunella Favilli, RT
Assuro Giorgetti, MD
Alessia Gimelli, MD

*Fondazione Toscana G. Monasterio
Via G. Moruzzi 1
56124 Pisa, Italy
E-mail: gimelli@ftgm.it


© 2022 by the American College of Cardiology Foundation. Published by Elsevier.

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

REFERENCES


Myocardial Fibrosis Quantified by Cardiac CT Predicts Outcome in Severe Aortic Stenosis After Transcatheter Intervention

In severe aortic stenosis (AS), the timing of surgical aortic valve replacement or transcatheter aortic valve replacement (TAVR) is currently determined by the hemodynamic status of the valve and symptoms, but it is the myocardial damage caused by myocardial fibrosis (MF) that determines outcome after successful intervention (1). Furthermore, dual AS and cardiac amyloidosis (CA) have been detected in 13% to 16% of elderly patients with AS referred for TAVR, adding to the case for myocardial assessment in AS (2). The detection of MF and CA was previously limited to invasive biopsy or cardiovascular magnetic resonance (CMR); neither is suitable for elderly patients referred for TAVR, the dominant mode of treatment in many countries. Contemporary work-up for TAVR includes cardiac computed tomography (CT), where quantification of extracellular volume by CT (ECVₜₐᵥ) can be performed without additional contrast. We sought to noninvasively evaluate the association of MF with outcome in patients with severe AS having excluded concomitant CA.

Patients with severe AS ≥75 years of age referred for TAVR underwent ECVₜₐᵥ as part of the ATTRact-AS (The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis) study (NCT03029026) protocol (3). This study complied with the Declaration of Helsinki and local ethics and site approvals; all patients provided written informed consent. Patients underwent ⁹⁹mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy to exclude CA, a TAVR computed tomographic protocol (SOMATOM Force, Siemens Healthineers) with
ECV<sub>CT</sub> (3), echocardiography, and N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T (hsTnT) measurement. The additional ECV<sub>CT</sub> acquisitions were precontrast baseline and 3 minutes postcontrast pseudoequilibrium axial shuttle-mode scans, triggered 250 ms after the R wave, analyzed using a dedicated ECV<sub>CT</sub> prototype for automatic 3-dimensional analysis (Siemens Healthineers). Managing clinicians were blinded to results of ECV<sub>CT</sub>. All-cause mortality was captured through national mortality registry interrogation. Extended Cox regression with temporal stratification was performed. Survival analysis was performed in R version 4.0.3 (R Foundation for Statistical Computing).

One hundred fifty patients underwent ECV<sub>CT</sub> and DPD scintigraphy, of whom 18 (12%) were excluded with dual AS-CA; 20 (15%) did not undergo TAVR. One hundred twelve patients (mean age 85 ± 5 years, 49% men) with severe AS (peak aortic valve jet velocity 4.1 ± 0.6 m/s, aortic valve area 0.7 ± 0.2 cm<sup>2</sup>) and a median ECV<sub>CT</sub> of 28.0% (IQR: 26.3%-29.7%) were included (Figure 1).

Over a follow-up of 21 months (IQR: 15-35 months), 27 deaths (24%) occurred. Only ECV<sub>CT</sub> (HR: 1.246; \( P = 0.004 \)) and right ventricular function (tricuspid annular plane systolic excursion; HR: 0.372; \( P = 0.017 \)) were univariate Cox regression predictors. Excluding patients with focal ECV elevation likely corresponding to myocardial infarction (\( n = 13 \) [12%]), ECV<sub>CT</sub> remained associated with outcome (\( P = 0.02 \)), with a similar HR (1.22 vs 1.25). On multivariate extended Cox regression, short-term mortality hazard doubled as hsTnT doubled, and medium-term mortality (>1.5 years) doubled for every 2% increase in ECV<sub>CT</sub> and every 4-mm reduction in tricuspid annular plane systolic excursion (\( P < 0.0001 \)).

ECV<sub>CT</sub> as part of the preprocedural cardiac CT predicts outcome after TAVR even after exclusion of dual AS-CA. ECV<sub>CT</sub> therefore serves as a robust screening tool not only for the detection of AS-CA (3) but also for risk stratification in lone AS. ECV<sub>CT</sub> as a marker of MF predicts medium-term outcome together with right heart function, whereas short-term outcome is predicted by myocardial injury (hsTnT). Compared with CMR, ECV<sub>CT</sub> is a faster alternative, offering 3-dimensional isotropic, whole-heart ECV quantification, and it can be integrated into routine preprocedural CT for TAVR without additional iodine contrast, with minimal additional radiation and scan time. Although limited by a small number of events restricting adjustment for confounders, the key strength is the exclusion of 1 in 7 patients with AS-CA, who would have fallen in the high ECV<sub>CT</sub> category (3). Previous studies showing an association of ECV<sub>CT</sub> with adverse clinical outcomes post-TAVR could not differentiate fibrosis from amyloidosis as cause of ECV elevation (4), a key missing diagnostic step to target appropriate management (ie, amyloidosis-targeted vs fibrosis-targeted therapeutics) (5). So what is the role of ECV<sub>CT</sub> in patients under evaluation for TAVR? First, it can be used to identify patients with concomitant AS-CA in order to offer amyloidosis-specific therapies after TAVR. Second, ECV<sub>CT</sub> can aid in risk stratification according to fibrosis burden, potentially guiding clinicians as to the optimal...
Coronary artery anomalies are an important cause of sudden cardiac death in young competitive athletes. Current imaging guidelines for young competitive athletes recommend routine assessment of proximal coronary anatomy to assess for the presence of high-risk anomalies regardless of the indication for transthoracic echocardiography (TTE). Prior studies have documented the ability of TTE to define proximal coronary anatomy, but the frequency with which proximal coronary origins are evaluated and reported in real-world practice remains unknown. The primary aim of this study was to examine the reporting frequency of proximal coronary anatomy among echocardiography laboratories in ORCCA (Outcomes Registry for Cardiac Conditions in Athletes).

This prospective observational cohort study included colleges from the National Collegiate Athletic Association that submitted data to ORCCA from September 1, 2020, to May 21, 2021, as previously reported. The inclusion criterion for this study was at least 1 TTE report from a participating echocardiography laboratory. A total of 56 echocardiography laboratories met this inclusion criterion. All available TTE reports were reviewed to assess for the presence of proximal coronary anatomy and the ability to visualize coronary origins in >90% of clinical reports, while “variable reporters” were defined as laboratories that reported coronary data <90% of the time. All aspects of this study were approved by the Massachusetts General Brigham Institutional Review Board (protocol #2020PO02667).

Complete reports were available for 1,529 of 3,027 athletes (51%) who underwent transthoracic echocardiographic screening (mean age 20 ± 3 years, 31% women, 27% Black race), representing 25 unique institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

REFERENCES


